QCT Collaborates with Samsung and Intel to Lead Transition to PCIe Gen5 with Next-Generation Servers and SSDs
26.7.2022 06:51:00 EEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced the world’s first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe™ servers powered by 4th Gen Intel® Xeon® Scalable processors. 4th Gen Intel Xeon Scalable processors will deliver substantial compute performance across traditional data center usages with unique purpose-built workload optimizations for today’s edge to cloud models. These technology updates in QCT’s growing line of QuantaGrid servers add additional performance for Samsung’s high-bandwidth flash storage due to the 4th Gen Intel Xeon Scalable processors support of leading industry standard technologies such as DDR5, Intel® Optane™ persistent memory, and PCIe Gen5. Furthermore, these unique solutions provide flexibility for modern data center needs ranging from low latency applications to data processing, and hyper-converged infrastructures (HCI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005386/en/
SVP & GM of QCT, Mike Yang (left) and EVP of Samsung Electronics, Yongcheol Bae (right) announce collaboration to pioneer PCIe Gen5 SSD systems (Photo: Business Wire)
To accommodate the rapidly increasing performance requirements of data centers, PCIe Gen5 doubles IOPS per watt and throughput compared to the previous generation. Samsung’s PM1743 SSD for enterprise servers integrates the PCIe Gen5 interface with Samsung’s advanced sixth-generation V-NAND to deliver 30% enhanced power efficiency than the previous generation, resulting in lower server operating costs and increasing scalability for virtualized environments like HCI and software-defined storage.
With the evolution of data centers to the rapid growth of data and proliferation of applications that demand high performance, QCT’s upcoming QuantaGrid series offer flexibility for scaling out with Samsung’s new storage innovation. The QuantaGrid D54X-1U and D54Q-2U are designed for dual 4th Gen Intel Xeon Scalable processors with 32 DDR5 DIMM slots and support for Intel Optane persistent memory, which provides affordable memory capacity expansion and support for data persistence. The two servers mainly differ in storage capacity and number of expansion slots that will be further revealed with the release of 4th Gen Intel Xeon Scalable processors.
“QCT worked closely with Samsung to test and be among the first to validate Samsung’s PM1743 PCIe Gen5 SSDs on our Intel powered systems,” said Mike Yang, President of QCT. “Together with Samsung, and Intel, our technology leadership will continue to drive new applications as we accelerate the growth of the server market and deliver unparalleled performance advantages for IOPS-intensive applications.”
"Samsung has been working closely with QCT and Intel to show PCIe Gen5 PM1743 SSDs provide optimized performance for all-flash NVMe workloads in their QuantaGrid 1U and 2U systems," said Yongcheol Bae, Executive Vice President of the Memory Application Engineering Team at Samsung Electronics. “Collectively, with the introduction of our PCIe Gen5 SSD, Intel’s 4th Gen Xeon Scalable processors, and QCT’s QuantaGrid server line we will further solidify our technological leadership in the enterprise server market.”
“Our goal is to deliver industry leadership to accelerate data center performance and user experiences with our upcoming 4th Gen Intel Xeon Scalable processors,” said Zane Ball, Intel Corporate Vice President and General Manager of Data Platforms Engineering and Architecture. “The collaboration with QCT and Samsung signifies Intel’s commitment to providing our customers with a multitude of ways to enhance their applications with high-speed NVMe SSDs that enable deployments from edge to cloud.”
Follow QCT on Facebook and Twitter to receive their latest news and announcements.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT
QCT is a global datacenter solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. www.QCT.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005386/en/
Contact information
Janet Chang
Janet.chang@quantatw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom